Oclacitinib Overview

Oclacitinib is an FDA-approved Janus kinase (JAK) inhibitor that primarily targets JAK-1 and JAK-3 signaling pathways. By inhibiting these pathways, it effectively blocks inflammatory cytokines such as IL-2, IL-4, IL-6, IL-13, and IL-31, which are directly involved in causing itch. Unlike steroids, antihistamines, Cytopoint, or cyclosporine, oclacitinib acts rapidly and has a low risk of gastrointestinal side effects.

Mechanism of Action

Oclacitinib provides significant itch relief within 24 hours, with its antipruritic effect lasting for 12–24 hours, which is why it typically requires daily administration for ongoing efficacy.

Dosing and Administration for Dogs

• Initial Phase (up to 14 days): Administer 0.4–0.6 mg/kg every 12 hours.

• Maintenance Phase: After the initial phase, transition to a daily dose of 0.4–0.6 mg/kg once a day.

Long-term use of twice-daily dosing is off-label and not FDA approved. It is essential to adhere strictly to the recommended dosage range to avoid excessive immunosuppression, although some mild cases may respond to lower doses.

Clinical Response

Most dogs experience complete itch relief within a few days. However, concurrent infections (such as yeast, bacterial, or mite infections) may reduce the drug’s effectiveness. Approximately 60% of dogs with moderate to severe cases achieve long-term control with once-daily dosing. Severe cases may benefit from twice-daily dosing, but this is off-label. In many cases, combination therapy may be necessary for optimal control.

Drug Interactions and Safety

Although JAK inhibitors in humans may interact with strong CYP3A4 inhibitors like ketoconazole, no significant adverse interactions have been observed in dogs. No long-term studies have assessed the use of oclacitinib in combination with other immunosuppressants. Short-term steroid use (0.5 mg/kg twice daily with taper) appears safe. If combining steroids with oclacitinib, evaluate its effectiveness before tapering steroids to avoid an adrenal crisis.

Age Restrictions

Oclacitinib is approved for use in dogs over 12 months old. Puppies under 1 year may experience high rates of demodicosis and pneumonia at doses three to five times the regular dose, and the drug is less effective in this age group.

Adverse Effects in Dogs

Common side effects include:

• Vomiting, diarrhea, lethargy, anorexia

• Subcutaneous or dermal masses, decreased leukocytes or globulins

• Increased cholesterol or lipase levels

Less common side effects include:

• Demodicosis, neoplasia, pneumonia, bloody diarrhea, skin or ear infections, urinary tract infections, and histiocytomas.

Rarely, side effects may include polydipsia, increased appetite, aggression, or manic-like behavior, which resolve when the drug is discontinued. Bone marrow suppression occurs in approximately 1% of dogs, usually asymptomatically, detected only through bloodwork. Recovery is rapid after dose reduction.

Monitoring

Before starting treatment, obtain a baseline CBC and chemistry panel. Repeat bloodwork at two to three months and annually thereafter. The CBC is particularly important for detecting bone marrow suppression. Liver disease should be assessed before initiating therapy.

Off-Label Use in Cats

In cats, oclacitinib is used off-label to manage atopic dermatitis and other immune-mediated diseases. It often requires higher and more frequent dosing compared to dogs. In a study of 166 cats, 66% achieved adequate control, but 7% of these responders developed neutropenia within two to five months. Cats that fail to respond or cannot tolerate the drug within one month should be switched to alternative therapies. Bloodwork should be monitored at two months, five months, and every six months thereafter. Due to its off-label nature and potential side effects, feline cases should be managed by a veterinary dermatologist.

Summary

Oclacitinib provides rapid itch relief with a low likelihood of gastrointestinal side effects and rare long-term adverse effects. Its drawbacks include the need for regular monitoring for bone marrow suppression, variable efficacy, and limited long-term safety data. It is important to obtain bloodwork before starting therapy, repeat it at three months, and continue annual monitoring. For complete prescribing information, refer to the FDA-approved product insert.